title: Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis.
abstract: To further investigate the role of complement activation in Experimental Allergic Neuritis (EAN), the effect of systemic complement blockade by soluble CR1 (sCR1) was compared to complement depletion by Cobra Venom Factor (CVF) in EAN rats immunized with bovine peripheral nerve myelin. EAN rats treated with CVF (n = 10) had significantly reduced clinical scores compared to rats treated with sCR1 (n = 9) or saline (n = 10) (score: sCR1 0.66 +/- 0.7; CVF 0; saline 0.6 +/- 0.8; mean +/- SD). CVF treatment more effectively decreased inflammation and demyelination compared to sCR1 treatment which had only a partial effect (inflammation: sCR1 1.8 +/- 1.4; CVF 0.3 +/- 0.7; saline 1.9 +/- 1.2; demyelination; sCR1 1.3 +/- 1; CVF 0.1 +/- 0.6; saline 1.7 +/- 1.2). In lumbosacral nerve roots significantly less infiltrating ED1 positive macrophages and CD11bc (expressing complement receptor 3 or CR3) positive inflammatory cells were present in CVF treated EAN rats while there was a limited decrease in inflammation in the sCR1 treated animals compared to the saline treated rats (ED1: sCR1 1.4 +/- 1.2; CVF 0.5 +/- 0.6; saline 1.7 +/- 1.2; CD11bc: sCR1 1.9 +/- 1.2; CVF 0.9 +/- 1; saline 2.1 +/- 1.2). Our findings suggest that complement depletion by CVF is more effective than complement blockade by sCR1 in reducing the severity of inflammatory peripheral nerve demyelination.
authors.affiliation: Department of Neurology, University of Texas Health Science Center, Houston, USA.
authors.forename: F J
authors.initials: FJ
authors.lastname: Vriesendorp
authors.forename: R E
authors.initials: RE
authors.lastname: Flynn
authors.forename: M A
authors.initials: MA
authors.lastname: Pappolla
authors.forename: C L
authors.initials: CL
authors.lastname: Koski
mesh_terms: D000818:Animals; D015415:Biomarkers; D002417:Cattle; D003711:Demyelinating Diseases / Q000188:drug therapy / Q000276:immunology; D004546:Elapid Venoms / Q000627:therapeutic use*; D005260:Female; D007114:Immunization; D007150:Immunohistochemistry; D008264:Macrophages / Q000737:chemistry; D009186:Myelin Sheath / Q000276:immunology; D009444:Neuritis, Autoimmune, Experimental / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D011951:Receptors, Complement / Q000097:blood / Q000627:therapeutic use*; D012995:Solubility; D013126:Spinal Nerve Roots / Q000276:immunology / Q000473:pathology
chemical_list: D015415:Biomarkers; D004546:Elapid Venoms; D011951:Receptors, Complement